Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(14):1088-1089; doi:10.1093/jnci/95.14.1088
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Merchant, M. S.
Right arrow Articles by Thiele, C. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Merchant, M. S.
Right arrow Articles by Thiele, C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 14, 1088-1089, July 16, 2003
© 2003 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Potential Use of Imatinib in Ewing’s Sarcoma: Evidence for In Vitro and In Vivo Activity

Melinda S. Merchant, Carol J. Thiele

Affiliation of authors: Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Correspondence to: Melinda Merchant, M.D., Ph.D., National Cancer Institute, National Institutes of Health, 10 Center Dr. MSC 1298, Bldg. 10/13N240, Bethesda, MD 20892 (e-mail: merchanm@mail.nih.gov).

The first 10% of the full text of this article appears below.

We were quite interested in the findings of Tamborini et al. regarding evidence for KIT activation in a majority of Ewing’s sarcoma tumor specimens. This finding extends those from our laboratory (1) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?